On the stock market since 2019, it operates in the world of health and science. It has 145 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 67% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 63% a year on average.
Sales run at $218.7M a year. A small number, but proof the product has real buyers.
There is $639.4M in the vault; even if every debt were paid off, $611.5M would remain.
A loss of $113.7M against $218.7M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 23/100.
Right now the product sells for less than it costs to make; every sale deepens the loss. Council score: 3/10.
On our five-subject report card, IDYA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IDYA is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (52/100) says the stock isn’t cheap.